PART 01 EXECUTIVE SUMMARY PART 02 SCOPE OF THE REPORT PART 03 RESEARCH METHODOLOGY PART 04 MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05 MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 06 FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07 MARKET SEGMENTATION BY APPLICATION • Segmentation by application • Comparison by application • IHR – Market size and forecast 2017-2022 • Diarrhea remedies – Market size and forecast 2017-2022 • Others – Market size and forecast 2017-2022 • Market opportunity by application PART 08 CUSTOMER LANDSCAPE PART 09 REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Market opportunity PART 10 DECISION FRAMEWORK PART 11 DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12 MARKET TRENDS • Alternative products • Growing online pharmacy • 3D printing drugs PART 13 VENDOR LANDSCAPE • Overview • Landscape disruption PART 14 VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Sanofi • GlaxoSmithKline • Pfizer • Bayer Healthcare • Johnson & Johnson • Merck KGaA PART 15 APPENDIX • List of abbreviations Exhibit 01: Global metabolic disorder treatment market Exhibit 02: Global metabolic disorder treatment market Exhibit 03: Market characteristics Exhibit 05: Market definition – Inclusions and exclusions checklist Exhibit 06: Market size 2017 Exhibit 07: Validation techniques employed for market sizing 2017 Exhibit 08: Global – Market size and forecast 2017-2022 ($ bn) Exhibit 09: Global – Year-over-year growth 2018-2022 (%) Exhibit 10: Five forces analysis 2017 Exhibit 11: Five forces analysis 2022 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2017 Exhibit 18: Application – Market share 2017-2022 (%) Exhibit 19: Comparison by application Exhibit 20: IHR – Market size and forecast 2017-2022 ($ bn) Exhibit 21: IHR – Year-over-year growth 2018-2022 (%) Exhibit 22: Diarrhea remedies – Market size and forecast 2017-2022 ($ bn) Exhibit 23: Diarrhea remedies – Year-over-year growth 2018-2022 (%) Exhibit 24: Others - Market size and forecast 2017-2022 ($ bn) Exhibit 25: Others – Year-over-year growth 2018-2022 (%) Exhibit 26: Market opportunity by application Exhibit 27: Customer landscape Exhibit 28: Global – Market share by geography 2017-2022 (%) Exhibit 29: Regional comparison Exhibit 30: Americas – Market size and forecast 2017-2022 ($ bn) Exhibit 31: Americas – Year-over-year growth 2018-2022 (%) Exhibit 32: Top 3 countries in Americas Exhibit 33: EMEA – Market size and forecast 2017-2022 ($ bn) Exhibit 01: EMEA – Year-over-year growth 2018-2022 (%) Exhibit 02: Top 3 countries in EMEA Exhibit 03: APAC – Market size and forecast 2017-2022 ($ bn) Exhibit 04: APAC – Year-over-year growth 2018-2022 (%) Exhibit 05: Top 3 countries in APAC Exhibit 06: Market opportunity Exhibit 07: Global population 65+ 2010–2017 (%) Exhibit 08: Vendor landscape Exhibit 09: Landscape disruption Exhibit 10: Vendors covered Exhibit 11: Vendor classification Exhibit 12: Market positioning of vendors Exhibit 13: Sanofi overview Exhibit 14: Sanofi – Business segments Exhibit 15: Sanofi – Organizational developments Exhibit 16: Sanofi – Geographic focus Exhibit 17: Sanofi – Segment focus Exhibit 18: Sanofi – Key offerings Exhibit 19: GlaxoSmithKline overview Exhibit 20: GlaxoSmithKline – Business segments Exhibit 21: GlaxoSmithKline – Organizational developments Exhibit 22: GlaxoSmithKline – Geographic focus Exhibit 23: GlaxoSmithKline – Segment focus Exhibit 24: GlaxoSmithKline – Key offerings Exhibit 25: Pfizer overview Exhibit 26: Pfizer – Business segments Exhibit 27: Pfizer – Organizational developments Exhibit 28: Pfizer – Geographic focus Exhibit 29: Pfizer – Segment focus Exhibit 30: Pfizer – Key offerings Exhibit 31: Bayer Healthcare overview Exhibit 32: Bayer Healthcare – Business segments Exhibit 33: Bayer Healthcare – Organizational developments Exhibit 34: Bayer Healthcare – Geographic focus Exhibit 35: Bayer Healthcare – Segment focus Exhibit 36: Bayer Healthcare – Key offerings Exhibit 37: Johnson & Johnson overview Exhibit 38: Johnson & Johnson – Business segments Exhibit 39: Johnson & Johnson – Organizational developments Exhibit 40: Johnson & Johnson – Geographic focus Exhibit 41: Johnson & Johnson – Segment focus Exhibit 42: Johnson & Johnson – Key offerings Exhibit 43: Merck KGaA overview Exhibit 44: Merck KGaA – Business segments Exhibit 45: Merck KGaA – Organizational developments Exhibit 46: Merck KGaA– Geographic focus Exhibit 47: Merck KGaA – Segment focus Exhibit 48: Merck KGaA – Key offerings

Sanofi GlaxoSmithKline Pfizer Bayer Healthcare Johnson & Johnson Merck KGaA